


# What Is the Impact of Cyclophosphamide on Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant?

## STUDY DESIGN

**Retrospective multicenter cohort study comparing BOS incidence between patients receiving posttransplant cyclophosphamide (PTCy) prophylaxis vs those who do not**

## RESULTS

### Cumulative incidence of BOS by PTCy Use Adjusted HR, 0.25 (95% CI, 0.09-0.74)



PTCy prophylaxis ↓ BOS incidence by 75%

Mediation analysis demonstrated when chronic graft vs host disease added to model, PTCy HR attenuated from 0.26 to 0.41

- Chronic graft vs host disease prevention mediates PTCy's protective effect
- Results remained after excluding haploidentical transplants (HR, 0.24; 95% CI, 0.07-0.77)

In this study, PTCy was shown to significantly reduce BOS risk through prevention of chronic graft vs host disease.